Piper Jaffray Initiates Antares Pharma With Overweight

Piper Jaffray initiated coverage on Antares Pharma Inc ATRS with a Overweight rating. The target price for Antares Pharma is set to $3.50. Antares Pharma shares have dropped 27.27 percent over the past 52 weeks, while the S&P 500 index has surged 12.61 percent in the same period. Antares Pharma shares fell 4.15 percent to close at $2.08 on Friday.